Synthesis and antiviral evaluation of C-4-hydrazide derivatives of 2',3'-dideoxycytidine. 2001

V Boudou-Vivet, and C Mathé, and G Gosselin
Laboratoire de Chimie Organique Biomoléculaire de Synthèse, UMR 5625 CNRS-UM II, Université Montpellier II, Place E. Bataillon, 34095 Montpellier, France.

Syntheses of three hitherto unknown derivatives of 2',3'-dideoxycytidine, namely C-4-(salicylic hydrazide)-ddC, C-4-(N-butyloxycarbonyl-isoleucine hydrazide)-ddC and its N-unprotected chlorhydrate salt have been carried out. These compounds do not induce inhibition of HIV-1 replication in cell culture experiments. Nevertheless, the modifications on the base moiety increased in all cases the lipophilicity of the parent molecule with an acceptable water solubility compared to ddC.

UI MeSH Term Description Entries
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006834 Hydrazines Substituted derivatives of hydrazine (formula H2N-NH2). Hydrazide
D012995 Solubility The ability of a substance to be dissolved, i.e. to form a solution with another substance. (From McGraw-Hill Dictionary of Scientific and Technical Terms, 6th ed) Solubilities
D014779 Virus Replication The process of intracellular viral multiplication, consisting of the synthesis of PROTEINS; NUCLEIC ACIDS; and sometimes LIPIDS, and their assembly into a new infectious particle. Viral Replication,Replication, Viral,Replication, Virus,Replications, Viral,Replications, Virus,Viral Replications,Virus Replications
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D016047 Zalcitabine A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication at low concentrations, acting as a chain-terminator of viral DNA by binding to reverse transcriptase. Its principal toxic side effect is axonal degeneration resulting in peripheral neuropathy. 2',3'-Dideoxycytidine,Dideoxycytidine,ddC (Antiviral),HIVID Roche,Hivid,NSC-606170,2',3' Dideoxycytidine,NSC 606170,NSC606170
D019380 Anti-HIV Agents Agents used to treat AIDS and/or stop the spread of the HIV infection. These do not include drugs used to treat symptoms or opportunistic infections associated with AIDS. AIDS Drug,AIDS Drugs,Anti-AIDS Agents,Anti-AIDS Drug,Anti-HIV Agent,Anti-HIV Drug,Anti-AIDS Drugs,Anti-HIV Drugs,Agent, Anti-HIV,Agents, Anti-AIDS,Agents, Anti-HIV,Anti AIDS Agents,Anti AIDS Drug,Anti AIDS Drugs,Anti HIV Agent,Anti HIV Agents,Anti HIV Drug,Anti HIV Drugs,Drug, AIDS,Drug, Anti-AIDS,Drug, Anti-HIV,Drugs, AIDS,Drugs, Anti-AIDS,Drugs, Anti-HIV

Related Publications

V Boudou-Vivet, and C Mathé, and G Gosselin
January 1999, Nucleosides & nucleotides,
V Boudou-Vivet, and C Mathé, and G Gosselin
December 2003, Bioorganic & medicinal chemistry letters,
V Boudou-Vivet, and C Mathé, and G Gosselin
January 2008, Nucleic acids symposium series (2004),
V Boudou-Vivet, and C Mathé, and G Gosselin
January 2006, Journal of medicinal chemistry,
V Boudou-Vivet, and C Mathé, and G Gosselin
November 2003, Nucleosides, nucleotides & nucleic acids,
V Boudou-Vivet, and C Mathé, and G Gosselin
January 2013, Chemical & pharmaceutical bulletin,
V Boudou-Vivet, and C Mathé, and G Gosselin
June 2011, Bioorganic & medicinal chemistry letters,
V Boudou-Vivet, and C Mathé, and G Gosselin
January 2001, Nucleic acids research. Supplement (2001),
V Boudou-Vivet, and C Mathé, and G Gosselin
October 2010, Bioorganic & medicinal chemistry letters,
Copied contents to your clipboard!